AMGEN INC AMGEN ORD (CDI) news, videos and press releases
For more news please use our advanced search feature.
AMGEN INC AMGEN ORD (CDI) - More news...
AMGEN INC AMGEN ORD (CDI) - More news...
- AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE
- AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
- AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
- AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
- AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
- AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
- AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
- AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND
- AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS
- AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
- AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024
- AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
- AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE
- AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
- AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND
- AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS
- AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024
- AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
- AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
- AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
- AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
- AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
- AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
- AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
